Anixa Biosciences Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Anixa Biosciences Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $210.0K | Jan 10, 2025 |
| FY2023 | Oct 31, 2023 | $210.0K | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $512.0K | Jan 4, 2023 |
| FY2020 | Oct 31, 2019 | $250.0K | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $1.11M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $362.5K | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $300.0K | Jan 9, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2023 | $210.0K | Jan 10, 2025 |
| FY2022 | Oct 31, 2021 | $512.0K | Jan 4, 2023 |
| FY2020 | Oct 31, 2019 | $250.0K | Jan 7, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Oct 31, 2016 | $300.0K | Dec 8, 2016 |
| FY2016 | Oct 31, 2015 | $9.26M | Dec 8, 2016 |
| FY2015 | Oct 31, 2014 | $3.67M | Dec 23, 2015 |
| FY2014 | Oct 31, 2013 | $388.9K | Jan 29, 2015 |
| FY2012 | Oct 31, 2012 | $350 | Jan 29, 2013 |
| FY2012 | Jul 31, 2012 | $249.5K | Jan 29, 2013 |
| FY2012 | Apr 30, 2012 | $248.1K | Jan 29, 2013 |
| FY2012 | Jan 31, 2012 | $449.2K | Jan 29, 2013 |
| FY2012 | Oct 31, 2011 | $449.0K | Jan 29, 2013 |
| FY2012 | Jul 31, 2011 | $450.4K | Jan 29, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($10.93M) | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | ($12.55M) | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | ($9.81M) | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | ($13.60M) | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | ($12.95M) | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | ($10.02M) | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | ($11.65M) | Jan 7, 2021 |
| FY2018 | Oct 31, 2018 | ($14.00M) | Jan 11, 2019 |
| FY2018 | Oct 31, 2017 | ($5.01M) | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | ($5.02M) | Jan 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($11.70M) | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | ($13.83M) | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | ($11.01M) | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | ($13.88M) | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | ($13.14M) | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | ($9.98M) | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | ($11.89M) | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | ($14.29M) | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | ($6.08M) | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | ($4.51M) | Jan 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.07M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | $6.40M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | $4.77M | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | $6.70M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $6.19M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | $4.38M | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | $5.47M | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $6.81M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $1.60M | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $1.56M | Jan 9, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Oct 31, 2019 | $5.66M | Jan 9, 2020 |
| FY2019 | Oct 31, 2018 | $6.91M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $4.41M | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $2.71M | Jan 9, 2018 |
| FY2016 | Oct 31, 2015 | $5.51M | Dec 8, 2016 |
| FY2015 | Oct 31, 2014 | $6.41M | Dec 23, 2015 |
| FY2014 | Oct 31, 2013 | $7.99M | Jan 29, 2015 |
| FY2013 | Oct 31, 2012 | $2.86M | Jan 17, 2014 |
| FY2012 | Oct 31, 2011 | $2.87M | Jan 29, 2013 |
| FY2011 | Oct 31, 2010 | $2.89M | Jan 30, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($7.17M) | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | ($7.34M) | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | ($6.21M) | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | ($6.49M) | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | ($4.94M) | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | ($6.18M) | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | ($4.74M) | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | ($4.27M) | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | ($3.80M) | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | ($3.38M) | Jan 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 31, 2020 | $15.8K | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | $175.5K | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $38.4K | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $30.2K | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $146.5K | Jan 9, 2018 |
| FY2016 | Oct 31, 2015 | $54.8K | Dec 8, 2016 |
| FY2015 | Oct 31, 2014 | $6.7K | Dec 23, 2015 |
| FY2012 | Oct 31, 2012 | $1.6K | Jan 29, 2013 |
| FY2012 | Oct 31, 2011 | $9.0K | Jan 29, 2013 |
| FY2011 | Oct 31, 2010 | $2.1K | Jan 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $16.08M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | $21.59M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | $25.52M | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | $30.41M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $36.26M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | $9.45M | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | $6.29M | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $6.45M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $8.81M | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $5.63M | Jan 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.13M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | $2.70M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | $2.15M | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | $2.21M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $1.49M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | $1.19M | Jan 4, 2022 |
| FY2017 | Oct 31, 2017 | $889.5K | Jan 9, 2018 |
| FY2017 | Oct 31, 2016 | $4.64M | Jan 9, 2018 |
| FY2016 | Oct 31, 2015 | $4.28M | Dec 8, 2016 |
| FY2015 | Oct 31, 2014 | $5.05M | Dec 23, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $15.16M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | $20.00M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | $24.34M | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | $29.05M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $35.44M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | $8.76M | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | $5.24M | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $5.43M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | $7.92M | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | $987.5K | Jan 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($251.68M) | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | ($240.75M) | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | ($228.20M) | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | ($218.39M) | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | ($204.79M) | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | ($191.84M) | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | ($181.82M) | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | ($170.17M) | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | ($156.17M) | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | ($151.17M) | Jan 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.24M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | $1.27M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | $915.0K | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | $12.36M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | $29.13M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | $6.42M | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | $3.49M | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | $3.06M | Jan 9, 2020 |
| FY2019 | Oct 31, 2017 | $3.34M | Jan 9, 2020 |
| FY2018 | Oct 31, 2016 | $2.49M | Jan 11, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2015 | $370.2K | Jan 29, 2015 |
| FY2015 | Oct 31, 2015 | $370.2K | Dec 23, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | 0 | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Jan 4, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 0 | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | 0 | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | 0 | Jan 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 33.01M | Jan 12, 2026 |
| FY2025 | Oct 31, 2024 | 32.20M | Jan 12, 2026 |
| FY2024 | Oct 31, 2023 | 31.15M | Jan 10, 2025 |
| FY2023 | Oct 31, 2022 | 30.91M | Jan 16, 2024 |
| FY2022 | Oct 31, 2021 | 30.05M | Jan 4, 2023 |
| FY2022 | Oct 31, 2020 | 24.25M | Jan 4, 2022 |
| FY2020 | Oct 31, 2019 | 20.33M | Jan 7, 2021 |
| FY2019 | Oct 31, 2018 | 18.91M | Jan 9, 2020 |
| FY2018 | Oct 31, 2017 | 16.60M | Jan 11, 2019 |
| FY2017 | Oct 31, 2016 | 8.75M | Jan 9, 2018 |